3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 2/3
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Hematologic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Interventions
Pemetrexed
13
Carboplatin
13
Docetaxel
11
Cisplatin
11
pembrolizumab
9
Paclitaxel
8
Gemcitabine
7
Erlotinib Hydrochloride
4
Bevacizumab
4
anlotinib
3
Radiotherapy
3
Magnetic Resonance Spectroscopy
3
Gefitinib
3
Dexamethasone
3
dexamethasone acetate
2
dexamethasone 21-phosphate
2
cobimetinib
2
cemiplimab
2
auricularum
2
atezolizumab
2
apatinib
2
Vemurafenib
2
Surgical Procedures, Operative
2
Standard of Care
2
Specimen Handling
2
Ramucirumab
2
Calcium Dobesilate
2
trametinib
1
toripalimab
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Carcinoma, Non-Small-Cell Lung
×
Vemurafenib
×
Clear all
NCT03178552
2026-06-05
B-FAST
Hoffmann-La Roche
Phase 2/3
Active not recruiting
1,000 enrolled
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled